Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MST1R | Q04912 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 19/20 | 0.38 |
| ▸ | KDR | P35968 | 19/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664093 | 0.93 | MST1R (0.48) | MST1RMETKDR | |
| SCHEMBL2602335 | 0.84 | MST1R (0.58) | MST1RMETKDR | |
| SCHEMBL2602355 | 0.83 | MST1R (0.46) | MST1RMETKDR | |
| SCHEMBL2670828 | 0.83 | MET (0.40) | MST1RMETKDR | |
| SCHEMBL12734206 | 0.83 | MST1R (0.47) | MST1RMETKDR | |
| SCHEMBL19027051 | 0.83 | MST1R (0.47) | MST1RMETKDR | |
| SCHEMBL10164585 | 0.81 | MET (0.42) | MST1RMETKDR | |
| SCHEMBL12229305 | 0.81 | MST1R (0.51) | MST1RMETKDR | |
| SCHEMBL12229244 | 0.81 | MET (0.52) | METKDR | |
| SCHEMBL12754688 | 0.80 | MST1R (0.48) | MST1RMETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MST1R 104/4885MET 3/4885KDR 11/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MST1R 104/4885MET 3/4885KDR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.